Literature DB >> 20614457

Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD).

Sarah E Hetrick1, Rosemary Purcell, Belinda Garner, Ruth Parslow.   

Abstract

BACKGROUND: PTSD is an anxiety disorder related to exposure to a severe psychological trauma. Symptoms include re-experiencing the event, avoidance and arousal as well as distress and impairment resulting from these symptoms.Guidelines suggest a combination of both psychological therapy and pharmacotherapy may enhance treatment response, especially in those with more severe PTSD or in those who have not responded to either intervention alone.
OBJECTIVES: To assess whether the combination of psychological therapy and pharmacotherapy provides a more efficacious treatment for PTSD than either of these interventions delivered separately. SEARCH STRATEGY: Searches were conducted on the trial registers kept by the CCDAN group (CCDANCTR-Studies and CCDANCTR-References) to June 2010. The reference sections of included studies and several conference abstracts were also scanned. SELECTION CRITERIA: Patients of any age or gender, with chronic or recent onset PTSD arising from any type of event relevant to the diagnostic criteria were included. A combination of any psychological therapy and pharmacotherapy was included and compared to wait list, placebo, standard treatment or either intervention alone. The primary outcome was change in total PTSD symptom severity. Other outcomes included changes in functioning, depression and anxiety symptoms, suicide attempts, substance use, withdrawal and cost. DATA COLLECTION AND ANALYSIS: Two or three review authors independently selected trials, assessed their 'risk of bias' and extracted trial and outcome data. We used a fixed-effect model for meta-analysis. The relative risk was used to summarise dichotomous outcomes and the mean difference and standardised mean difference were used to summarise continuous measures. MAIN
RESULTS: Four trials were eligible for inclusion, one of these trials (n =24) was on children and adolescents. All used an SSRI and prolonged exposure or a cognitive behavioural intervention. Two trials compared combination treatment with pharmacological treatment and two compared combination treatment with psychological treatment. Only two trials reported a total PTSD symptom score and these data could not be combined. There was no strong evidence to show if there were differences between the group receiving combined interventions compared to the group receiving psychological therapy (mean difference 2.44, 95% CI -2.87, 7.35 one study, n=65) or pharmacotherapy (mean difference -4.70, 95% CI -10.84 to 1.44; one study, n = 25). Trialists reported no significant differences between combination and single intervention groups in the other two studies. There were very little data reported for other outcomes, and in no case were significant differences reported. AUTHORS'
CONCLUSIONS: There is not enough evidence available to support or refute the effectiveness of combined psychological therapy and pharmacotherapy compared to either of these interventions alone. Further large randomised controlled trials are urgently required.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20614457     DOI: 10.1002/14651858.CD007316.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  48 in total

Review 1.  Fear extinction and BDNF: translating animal models of PTSD to the clinic.

Authors:  R Andero; K J Ressler
Journal:  Genes Brain Behav       Date:  2012-05-11       Impact factor: 3.449

2.  Acute tianeptine treatment selectively modulates neuronal activation in the central nucleus of the amygdala and attenuates fear extinction.

Authors:  B P Godsil; B Bontempi; F Mailliet; P Delagrange; M Spedding; T M Jay
Journal:  Mol Psychiatry       Date:  2015-01-06       Impact factor: 15.992

3.  Refugee children: mental health and effective interventions.

Authors:  Laura Pacione; Toby Measham; Cécile Rousseau
Journal:  Curr Psychiatry Rep       Date:  2013-02       Impact factor: 5.285

4.  The glucocorticoid receptor-FKBP51 complex contributes to fear conditioning and posttraumatic stress disorder.

Authors:  Haiyin Li; Ping Su; Terence Ky Lai; Anlong Jiang; Jing Liu; Dongxu Zhai; Charlie Tg Campbell; Frankie Hf Lee; WeiDong Yong; Suvercha Pasricha; Shupeng Li; Albert Hc Wong; Kerry J Ressler; Fang Liu
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

Review 5.  Treatment of substance abusing patients with comorbid psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  Addict Behav       Date:  2011-09-14       Impact factor: 3.913

Review 6.  Animal models of fear relapse.

Authors:  Travis D Goode; Stephen Maren
Journal:  ILAR J       Date:  2014

Review 7.  Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults.

Authors:  Jonathan I Bisson; Neil P Roberts; Martin Andrew; Rosalind Cooper; Catrin Lewis
Journal:  Cochrane Database Syst Rev       Date:  2013-12-13

8.  Augmenting Prolonged Exposure therapy for PTSD with intranasal oxytocin: A randomized, placebo-controlled pilot trial.

Authors:  Julianne C Flanagan; Lauren M Sippel; Amy Wahlquist; Megan M Moran-Santa Maria; Sudie E Back
Journal:  J Psychiatr Res       Date:  2017-12-26       Impact factor: 4.791

9.  Enhancing prolonged exposure therapy for PTSD among veterans with oxytocin: Design of a multisite randomized controlled trial.

Authors:  Julianne C Flanagan; Jennifer M Mitchell; Nathaniel L Baker; Joshua Woolley; Bethany Wangelin; Sudie E Back; John R McQuaid; Thomas C Neylan; William R Wolfe; Kathleen T Brady
Journal:  Contemp Clin Trials       Date:  2020-06-16       Impact factor: 2.226

Review 10.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.